title: Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies.
abstract: Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2+/-3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A+C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98 versus 1.63, P<0.001) and the control group (12.13 versus 1.26, P<0.001). All controls had a protective SBA response (SBA titre of >or=8 post-vaccination or rise of >or=4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response (P=0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients.
authors.affiliation: Department of Allergy and Clinical Immunology of Children Medical Center, Immunology, Asthma and Allergy Research Institute, Medical Sciences/University of Tehran, Tehran, Iran. rezaei_nima@hbi.ir
authors.forename: Nima
authors.initials: N
authors.lastname: Rezaei
authors.forename: Asghar
authors.initials: A
authors.lastname: Aghamohammadi
authors.forename: Seyed Davar
authors.initials: SD
authors.lastname: Siadat
authors.forename: Mehdi
authors.initials: M
authors.lastname: Nejati
authors.forename: Hojat
authors.initials: H
authors.lastname: Ahmadi
authors.forename: Mostafa
authors.initials: M
authors.lastname: Moin
authors.forename: Zahra
authors.initials: Z
authors.lastname: Pourpak
authors.forename: Samineh
authors.initials: S
authors.lastname: Kamali
authors.forename: Dariush
authors.initials: D
authors.lastname: Norouzian
authors.forename: Bahman
authors.initials: B
authors.lastname: Tabaraei
authors.forename: Robert C
authors.initials: RC
authors.lastname: Read
mesh_terms: D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D008297:Male; D022401:Meningococcal Vaccines / Q000276:immunology*; D050296:Microbial Viability; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines